Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Dr. Makarand Jawadekar, Ph.D
Independent Pharma Professional
About the author:
Dr. Mak Jawadekar is currently an independent Pharma Professional. He worked at Pfizer Inc. based in Groton-New London Connecticut for 28 consecutive years. He worked as a Director, Portfolio Management. During his career at Pfizer, he was responsible for Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies. He has extensive experience in creating and cultivating external partnerships and alliances for drug delivery technologies. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota..Mak was honored with an honorary D.Sc. degree by DYP Mumbai University, recommended by the President of India in Feb 2011.
Posts by Dr. Makarand Jawadekar, Ph.D
Posted on July 10th, 2017 in Pharma R&D
The pharmaceutical industry had really been quite optimistic as of late regarding regulatory overhaul and getting rid of the ever-present ‘red tape’ within the regulatory body in the US, and the FDA had shown a very positive response towards getting biosimilars approved. Continue reading “Biosimilars Development & its Future” »
Posted on July 5th, 2017 in Pharma R&D
These days, there is a lot of focus on nutraceuticals and ‘natural products’, derived from nature or alternately synthesized as ‘nature-identical compounds’ and used in nutraceuticals products. Continue reading “Focus on Nutraceuticals & Natural Products: Medical Use of Cannabis” »
Posted on June 2nd, 2017 in Pharma R&D
Since 1906, the US Food and Drug Administration (FDA) through regulations has been responsible for ensuring the approval of new drugs whose health benefits outweigh the known risks associated with the drug.
Posted on March 2nd, 2017 in Pharma R&D
Cancer. It’s the 2nd leading cause of death in this country (1), and a disease feared by patients and healthcare professionals alike. Today’s cancer treatments vary in nature, and also, efficacy and levels of side effect profiles. Continue reading “Emerging Oncology Drugs in Pharma R&D Pipeline” »